Zbyněk N.
- Country
- Czechia
- Department
- Department of Pediatrics
Research Overview
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Evaluation of Bortezomib, Blinatumomab, and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Randomized Controlled Trial
- Evaluation of Dexamethasone Versus Prednisone in Induction Therapy for Pediatric and Adolescent Lymphoblastic Lymphoma: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 177 of 247 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute lymphoblastic leukemia (ALL), with particular expertise in pediatric and adolescent cases. Their research focuses on advanced therapeutic approaches for this aggressive blood cancer.
- Philadelphia chromosome-positive ALL
- Pediatric leukemia treatments
- Risk-stratified therapy approaches
The investigator works with various risk categories of ALL patients, implementing tailored treatment strategies based on genetic profiles and treatment responses.
Therapeutic Innovation
Their clinical interests encompass the evaluation of novel therapeutic combinations in leukemia treatment, including targeted therapies and immunotherapy approaches.
- Targeted molecular therapies
- Immunotherapy protocols
- Chemotherapy optimization
The investigator explores innovative treatment protocols that combine established chemotherapy backbones with newer therapeutic agents.
Treatment Response Assessment
The investigator focuses on treatment response evaluation and risk stratification in leukemia patients, developing adaptive therapeutic strategies.
- Disease-free survival assessment
- Risk-based treatment adaptation
- Response monitoring protocols
Their work involves careful monitoring of treatment outcomes and adjustment of therapeutic approaches based on patient response patterns.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.